Quest Diagnostics (DGX) PT Raised to $104.50 at Evercore ISI

Evercore ISI raised its price target on Quest Diagnostics (NYSE: DGX) to $104.50 (from $102.00) while maintaining an In Line rating.

Analyst Ross Muken said DGX has become one of the most consistent companies in healthcare. That said, valuation keeps them on the sidelines.

The firm raised FY 2017 EPS from $5.52 to $5.55, FY 2018 EPS was lowered to $5.90 from $5.95 and FY 2019 EPS was lowered from $6.70 to $6.55.

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• MDA Ltd (MDA:CN) (MDALF) PT Raised to Cdn$64 at CIBC
• Plexus (PLXS) PT Raised to $330 at Stifel